Schizophrenia

• 

  Subject Areas on Research

  • "Like a doctor, like a brother": Achieving competence amongst lay health workers delivering community-based rehabilitation for people with schizophrenia in Ethiopia. 
  • 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. 
  • 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. 
  • A Cohort Study of Mortality in Individuals With and Without Schizophrenia After Diagnosis of Lung Cancer. 
  • A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. 
  • A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. 
  • A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. 
  • A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. 
  • A cognitive investigation of schizophrenic delusions. 
  • A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. 
  • A comparison of stigmatizing attitudes toward persons with schizophrenia in four stakeholder groups: perceived likelihood of violence and desire for social distance. 
  • A fully automated method for tissue segmentation and CSF-correction of proton MRSI metabolites corroborates abnormal hippocampal NAA in schizophrenia. 
  • A genome-wide investigation of SNPs and CNVs in schizophrenia. 
  • A longitudinal examination of the psychoeducational, neurocognitive, and psychiatric functioning in children with 22q11.2 deletion syndrome. 
  • A longitudinal study of neurocognitive function in individuals at-risk for psychosis. 
  • A multi-scanner study of subcortical brain volume abnormalities in schizophrenia. 
  • A national study of violent behavior in persons with schizophrenia. 
  • A new measure of authentic auditory emotion recognition: Application to patients with schizophrenia. 
  • A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. 
  • A pilot study of a structured interview addressing sexual function in men with schizophrenia. 
  • A pilot study of a weight management program with food provision in schizophrenia. 
  • A pilot study of assertive community treatment for patients with chronic psychotic disorders. 
  • A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. 
  • A quality improvement process for implementing the Texas algorithm for schizophrenia in Ohio. 
  • A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale. 
  • A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. 
  • A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. 
  • A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. 
  • A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. 
  • A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia. 
  • A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. 
  • A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. 
  • A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. 
  • AKT1 and neurocognition in schizophrenia. 
  • APOE2 allele increased in tardive dyskinesia. 
  • Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. 
  • Abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia. 
  • Abnormalities of the corpus callosum in nonpsychotic children with chromosome 22q11 deletion syndrome. 
  • Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia. 
  • Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs. 
  • Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. 
  • Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. 
  • Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. 
  • Altered functional connectivity in psychotic disorder not otherwise specified. 
  • Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. 
  • Alternative Perspectives on Police Encounters and Psychotic Experiences [Invited Commentary on DeVylder et al, "Psychotic Experiences in the Context of Police Victimization"]. 
  • Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. 
  • An analysis of cue reactivity among persons with and without schizophrenia who are addicted to cocaine. 
  • An assessment of the understanding and motivations of patients with schizophrenia about participating in a clinical trial. 
  • An emerging schizophrenic syndrome. 
  • An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. 
  • An evidence synthesis of care models to improve general medical outcomes for individuals with serious mental illness: a systematic review. 
  • An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. 
  • An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. 
  • Analysing an allelic series of rare missense variants of CACNA1I in a Swedish schizophrenia cohort. 
  • Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders. 
  • Anticipating DSM-V: opportunities and challenges for cognition and psychosis. 
  • Antipsychotic drug effects on brain morphology in first-episode psychosis. 
  • Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis. 
  • Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. 
  • Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. 
  • Antipsychotic-induced weight gain and therapeutic response: a differential association. 
  • Applications of TMS to therapy in psychiatry. 
  • Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. 
  • Aripiprazole: pharmacology, efficacy, safety and tolerability. 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Assertive community treatment: an update of randomized trials. 
  • Assessing causal relationships using genetic proxies for exposures: an introduction to Mendelian randomization. 
  • Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. 
  • Assessing illicit drug use among adults with schizophrenia. 
  • Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia. 
  • Assessment of four stakeholder groups' preferences concerning outpatient commitment for persons with schizophrenia. 
  • Association between genetic and socioenvironmental risk for schizophrenia during upbringing in a UK longitudinal cohort. 
  • Association between genetic variation at the porphobilinogen deaminase gene and schizophrenia. 
  • Association of an Early Intervention Service for Psychosis With Suicide Rate Among Patients With First-Episode Schizophrenia-Spectrum Disorders. 
  • Associations between purine metabolites and clinical symptoms in schizophrenia. 
  • Associations between variants near a monoaminergic pathways gene (PHOX2B) and amygdala reactivity: a genome-wide functional imaging study. 
  • Asymmetry of rCBF in schizophrenia: relationship to AP-gradient and duration of illness. 
  • Attention deficits in schizophrenia--preliminary evidence of dissociable transient and sustained deficits. 
  • Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia. 
  • Attentional functioning in schizotypal personality disorder. 
  • Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. 
  • Atypical antipsychotics and pituitary neoplasms in the WHO database. 
  • Autism, Psychosis, or Both? Unraveling Complex Patient Presentations. 
  • Autobiographical and episodic memory deficits in schizophrenia: A narrative review and proposed agenda for research. 
  • Autobiographical memory and the self on the psychosis continuum: investigating their relationship with positive- and negative-like symptoms. 
  • Barriers to employment for people with schizophrenia. 
  • Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. 
  • Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia. 
  • Bayard Holmes (1852-1924) and Henry Cotton (1869-1933): Surgeon-psychiatrists and their tragic quest to cure schizophrenia. 
  • Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit. 
  • Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. 
  • Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. 
  • Body mass index and future schizophrenia in Israeli male adolescents. 
  • Brain volumes in psychotic youth with schizophrenia and mood disorders. 
  • Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. 
  • CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al. 
  • COMT158 polymorphism and hostility. 
  • Can IQ moderate the response to cognitive remediation in people with schizophrenia? 
  • Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. 
  • Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. 
  • Catechol O-methyltransferase in red blood cells of schizophrenic, depressed, and normal human subjects. 
  • Cerebral blood flow responses to inhaled carbon dioxide in schizophrenia. 
  • Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. 
  • Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients. 
  • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. 
  • Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. 
  • Characteristics of schizophrenic and depressed patients excluded from clinical research. 
  • Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. 
  • Characteristics of very poor outcome schizophrenia. 
  • Characterization of a Human-Specific Tandem Repeat Associated with Bipolar Disorder and Schizophrenia. 
  • Childhood IQ and adult mental disorders: a test of the cognitive reserve hypothesis. 
  • Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. 
  • Chronicity and a low anteroposterior gradient of cerebral blood flow in schizophrenia. 
  • Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies. 
  • Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. 
  • Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. 
  • Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. 
  • Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. 
  • Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? 
  • Clozapine decreases smoking in patients with chronic schizophrenia. 
  • Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). 
  • Clozapine treatment reverses dizocilpine-induced deficits of pre-pulse inhibition of tactile startle response. 
  • Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. 
  • Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia. 
  • Cognition as an outcome measure in schizophrenia. 
  • Cognition in schizophrenia: summary Nice Consultation Meeting 2012. 
  • Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia. 
  • Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. 
  • Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. 
  • Cognitive burden of anticholinergic medications in psychotic disorders. 
  • Cognitive deficits in patients with schizophrenia: effects and treatment. 
  • Cognitive disparity in schizophrenics with and without cocaine dependency. 
  • Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). 
  • Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. 
  • Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. 
  • Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. 
  • Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. 
  • Cognitive impairment as a target for pharmacological treatment in schizophrenia. 
  • Cognitive impairment in schizophrenia. 
  • Combining gene expression, demographic and clinical data in modeling disease: a case study of bipolar disorder and schizophrenia. 
  • Common sense, insight, and neuropsychological test performance in schizophrenia patients. 
  • CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder. 
  • Community adjustment of older schizophrenics. 
  • Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. 
  • Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. 
  • Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials. 
  • Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. 
  • Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. 
  • Components and correlates of family burden in schizophrenia. 
  • Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia? 
  • Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). 
  • Concealed medicines for people with schizophrenia: a U.S. perspective. 
  • Consumers' perceptions of the fairness and effectiveness of mandated community treatment and related pressures. 
  • Continuation of clozapine during chemotherapy: a case report and review of literature. 
  • Continuity of antipsychotic medication management for Medicaid patients with schizophrenia. 
  • Continuity of medication management in Medicaid patients with chronic comorbid conditions: An examination by mental health status. 
  • Control for confounding in case-control studies using the stratification score, a retrospective balancing score. 
  • Convergent patterns of association between phenylalanine hydroxylase variants and schizophrenia in four independent samples. 
  • Convergent validity of the Timeline Followback for persons with comorbid psychiatric disorders engaged in residential substance use treatment. 
  • Converting positive and negative symptom scores between PANSS and SAPS/SANS. 
  • Convulsive threshold differences in right unilateral and bilateral ECT. 
  • Correlates of Future Violence in People Being Treated for Schizophrenia. 
  • Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. 
  • Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia. 
  • Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. 
  • Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. 
  • Cost-sharing requirements and access to mental health care among medicare enrollees with schizophrenia. 
  • Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. 
  • Covarying structural alterations in laterality of the temporal lobe in schizophrenia: A case for source-based laterality. 
  • Criminal justice system involvement among people with schizophrenia. 
  • Criminal victimization of persons with severe mental illness. 
  • Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. 
  • Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. 
  • Cumulative Effects of Neighborhood Social Adversity and Personal Crime Victimization on Adolescent Psychotic Experiences. 
  • Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. 
  • D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. 
  • Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. 
  • Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. 
  • Defining a cognitive function decrement in schizophrenia. 
  • Demographic and clinical characteristics associated with a history of bizarre delusions in a cross-diagnostic sample of individuals with psychotic disorders. 
  • Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder. 
  • Dentate gyrus volume deficit in schizophrenia. 
  • Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery. 
  • Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair. 
  • Determining when impairment constitutes incapacity for informed consent in schizophrenia research. 
  • Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. 
  • Development of a virtual reality assessment of everyday living skills. 
  • Development of nicotinic drug therapy for cognitive disorders. 
  • Development of the Thought Disorder Measure for the Hierarchical Taxonomy of Psychopathology. 
  • Diagnosis and disposition. 
  • Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. 
  • Differential patterns of initial and sustained responses in amygdala and cortical regions to emotional stimuli in schizophrenia patients and healthy participants. 
  • Diffusion tensor imaging: background, potential, and utility in psychiatric research. 
  • Dimensional diagnosis and the medical student's grasp of psychiatry. 
  • Disc1 regulates granule cell migration in the developing hippocampus. 
  • Disclosing diagnosis, continued. 
  • Discriminating imagined from perceived information engages brain areas implicated in schizophrenia. 
  • Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia. 
  • Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study. 
  • Does fear of coercion keep people away from mental health treatment? Evidence from a survey of persons with schizophrenia and mental health professionals. 
  • Does sigma receptor antagonism predict clinical antipsychotic efficacy? 
  • Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. 
  • Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. 
  • Dopaminergic abnormalities in Hdac6-deficient mice. 
  • Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. 
  • Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study. 
  • Drugs of the psychopharmacological revolution in clinical psychiatry. 
  • Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. 
  • Dysregulation of DGCR6 and DGCR6L: psychopathological outcomes in chromosome 22q11.2 deletion syndrome. 
  • ECT stimulus intensity: are present ECT devices too limited? 
  • Effect of ECT treatment number on the ictal EEG. 
  • Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. 
  • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 
  • Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. 
  • Effectiveness of atypical antipsychotics for substance use in schizophrenia patients. 
  • Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. 
  • Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. 
  • Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. 
  • Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. 
  • Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. 
  • Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. 
  • Effectiveness of switching from antipsychotic polypharmacy to monotherapy. 
  • Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. 
  • Effects of Schizophrenia Polygenic Risk Scores on Brain Activity and Performance During Working Memory Subprocesses in Healthy Young Adults. 
  • Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. 
  • Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. 
  • Effects of antipsychotic medications on sleep in schizophrenia. 
  • Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. 
  • Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. 
  • Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. 
  • Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. 
  • Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. 
  • Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. 
  • Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice. 
  • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. 
  • Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. 
  • Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. 
  • Efficacy of risperidone on positive features of schizophrenia. 
  • Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. 
  • Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. 
  • Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia. 
  • Electroconvulsive Therapy and All-Cause Mortality in Texas, 1998-2013. 
  • Electroconvulsive Therapy in Pregnancy: Safety, Best Practices, and Barriers to Care. 
  • Electroconvulsive therapy: an update. 
  • Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. 
  • Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories. 
  • Elevated hematocrit in patients with schizophrenia. 
  • Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. 
  • Emergency department visits among patients transported by law enforcement officers. 
  • Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. 
  • Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder. 
  • Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. 
  • Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. 
  • Epidemiology of late-life mental disorders. 
  • Establishing the Brief Assessment of Cognition - Short form. 
  • Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia. 
  • Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. 
  • Evaluating how treatment adherence influences cognitive remediation outcomes. 
  • Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure. 
  • Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. 
  • Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. 
  • Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. 
  • Evidence for altered cerebellar vermis neuronal integrity in schizophrenia. 
  • Evidence that altered amygdala activity in schizophrenia is related to clinical state and not genetic risk. 
  • Examining causal attributions for depression, alcohol use disorder, and schizophrenia in a diverse sample of international students at U.S. universities. 
  • Examining the relationship between adjunctive psychotherapy use and antipsychotic persistence and hospitalization. 
  • Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. 
  • Experimental physiological studies with lysergic acid diethylamide (LSD-25). 
  • Exploratory investigation of biomarker candidates for suicide in schizophrenia and bipolar disorder. 
  • Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. 
  • Extrapyramidal side-effects of antipsychotics in a randomised trial. 
  • Eye tracking impairment in clinically identified patients with schizotypal personality disorder. 
  • Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. 
  • Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. 
  • Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. 
  • Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia. 
  • Familial schizophrenia and treatment response. 
  • Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. 
  • Feasibility of client reports to measure treatment outcome in schizophrenia. 
  • Fetal brain development of twins assessed in utero by ultrasound: implications for schizophrenia. 
  • Fine-granularity functional interaction signatures for characterization of brain conditions. 
  • First- and second-generation antipsychotics. 
  • Fractal property of eye movements in schizophrenia. 
  • Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. 
  • Functional outcomes in schizophrenia. 
  • Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. 
  • GABA level, gamma oscillation, and working memory performance in schizophrenia. 
  • GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. 
  • Gene-environment interplay and psychopathology: multiple varieties but real effects. 
  • Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. 
  • Genetic correlates of insight in schizophrenia. 
  • Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. 
  • Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. 
  • Genetics and the geography of health, behaviour and attainment. 
  • Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. 
  • Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. 
  • Genome-wide Association Meta-analysis of Childhood and Adolescent Internalizing Symptoms. 
  • Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. 
  • Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. 
  • Genome-wide association study of treatment refractory schizophrenia in Han Chinese. 
  • Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. 
  • Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. 
  • Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. 
  • HHV-6 and Schizophrenia: An Unusual Presentation or an Unproven Etiology? 
  • Haase hermeneutics, or, the exegesis of the neuroleptic threshold. 
  • Haloperidol increases smoking in patients with schizophrenia. 
  • Heritability of functioning in families with schizophrenia in relation to neurocognition. 
  • Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. 
  • Hierarchical temporal processing deficit model of reality distortion and psychoses. 
  • High frequency EEG activity during sleep: characteristics in schizophrenia and depression. 
  • High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. 
  • High-frequency prefrontal repetitive transcranial magnetic stimulation for the negative symptoms of schizophrenia: a case series. 
  • High-performance liquid chromatography of haloperidol in serum at the concentrations achieved during chronic therapy. 
  • Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. 
  • Hospitalized schizophrenic patient views about seclusion. 
  • How should DSM-V criteria for schizophrenia include cognitive impairment? 
  • How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. 
  • IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. 
  • Identifying at risk nursing home residents using a polydipsia screening tool 
  • Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. 
  • Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. 
  • Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. 
  • Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. 
  • Impact of neuroleptic medications on continuous performance test measures in schizophrenia. 
  • Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. 
  • Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. 
  • Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS). 
  • Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. 
  • Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder. 
  • Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia. 
  • Impaired plasmalogens in patients with schizophrenia. 
  • Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. 
  • Implementation of the Texas Medication Algorithm Project patient and family education program. 
  • In the eye of the beholder: Perceptions of neighborhood adversity and psychotic experiences in adolescence. 
  • Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. 
  • Increased prevalence of falls among elderly individuals with mental health and substance abuse conditions. 
  • Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. 
  • Influence of Criminal Justice Involvement and Psychiatric Diagnoses on Treatment Costs Among Adults With Serious Mental Illness. 
  • Initial level of care and clinical status in a managed mental health program. 
  • Insight about psychosis among outpatients with schizophrenia. 
  • Insight in schizophrenia and mania. 
  • Insomnia is frequent in schizophrenia and associated with night eating and obesity. 
  • Integrated genetic and genomic approach in the SingaporeTranslational and Clinical Research in Psychosis Study: an overview. 
  • Interpersonal trauma, war zone exposure, and posttraumatic stress disorder among veterans with schizophrenia. 
  • Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. 
  • Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. 
  • Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms. 
  • Introduction to the CATIE special section. 
  • Introduction to the special section on CATIE baseline data: practical clinical trials in psychiatry: studies of schizophrenia from the CATIE network. 
  • Investigation of NRXN1 deletions: clinical and molecular characterization. 
  • Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. 
  • Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. 
  • Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. 
  • Ketamine ("Ketalar"): a safer anaesthetic for ECT. 
  • Ketamine potentiates oxidative stress and influences behavior and inflammation in response to lipolysaccharide (LPS) exposure in early life. 
  • Key updates in the clinical application of electroconvulsive therapy. 
  • Kraepelinian schizophrenia: a subgroup of schizophrenia? 
  • L-dopa challenge and relapse in schizophrenia. 
  • Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. 
  • Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions. 
  • Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. 
  • Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. 
  • Latent class analysis of discordance between results of drug use assessments in the CATIE data. 
  • Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). 
  • Letter to the editor: Critique of Bahorik et al. (2013)--'Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors'. 
  • Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder. 
  • Limbic circuits and neuropsychiatric disorders. Functional anatomy and neuroimaging findings. 
  • Linkage analysis of schizophrenia in African-American families. 
  • Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. 
  • Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. 
  • Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. 
  • MRI changes in schizophrenia in late life: a preliminary controlled study. 
  • MRI scans in patients with tardive dyskinesia. 
  • Machine learning approach to measurement of criticism: The core dimension of expressed emotion. 
  • Mapping genomic loci implicates genes and synaptic biology in schizophrenia. 
  • Measurements of plasma homovanillic acid in schizophrenic patients. 
  • Measures and predictors of community-based employment and earnings of persons with schizophrenia in a multisite study. 
  • Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. 
  • Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. 
  • Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. 
  • Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. 
  • Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes. 
  • Memory-prediction errors and their consequences in schizophrenia. 
  • Mental health care from the public perspective: the Texas Medication Algorithm Project. 
  • Meta-Modal Information Flow: A Method for Capturing Multimodal Modular Disconnectivity in Schizophrenia. 
  • Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. 
  • Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. 
  • Metabolic profiling of patients with schizophrenia. 
  • Metabolomic mapping of atypical antipsychotic effects in schizophrenia. 
  • Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. 
  • Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. 
  • Methodological issues in negative symptom trials. 
  • Methylomic analysis of monozygotic twins discordant for childhood psychotic symptoms. 
  • Microvascular abnormality in schizophrenia as shown by retinal imaging. 
  • Mild ventriculomegaly detected in utero with ultrasound: clinical associations and implications for schizophrenia. 
  • Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia? 
  • Multimodal Fusion With Reference: Searching for Joint Neuromarkers of Working Memory Deficits in Schizophrenia. 
  • Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion. 
  • NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. 
  • NCAM1 and neurocognition in schizophrenia. 
  • Neighborhood structural characteristics and mental disorder: Faris and Dunham revisited. 
  • Neural bases of different cognitive strategies for facial affect processing in schizophrenia. 
  • Neural correlates of automatic and controlled auditory processing in schizophrenia. 
  • Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. 
  • Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. 
  • Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. 
  • Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. 
  • Neurogranin, Encoded by the Schizophrenia Risk Gene NRGN, Bidirectionally Modulates Synaptic Plasticity via Calmodulin-Dependent Regulation of the Neuronal Phosphoproteome. 
  • Neuroimaging for psychotherapy research: current trends. 
  • Neuronal and glial 3D chromatin architecture informs the cellular etiology of brain disorders. 
  • Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. 
  • Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. 
  • Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. 
  • Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. 
  • Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. 
  • Neuropsychological profile in adult schizophrenia measured with the CMINDS. 
  • Neuropsychological status of subjects at high risk for a first episode of psychosis. 
  • Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. 
  • Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. 
  • Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. 
  • Nicotine-haloperidol interactions and cognitive performance in schizophrenics. 
  • Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. 
  • Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. 
  • Nicotinic treatment for cognitive dysfunction. 
  • Nicotinic-antipsychotic drug interactions and cognitive function. 
  • No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. 
  • Normal smooth pursuit eye movements in volunteer subjects meeting schizotypal personality disorder criteria. 
  • Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). 
  • Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia. 
  • Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. 
  • Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. 
  • Olanzapine on trial. 
  • On Thoughts, Threats, and Throwing the Spear. 
  • On sample size calculation based on odds ratio in clinical trials. 
  • One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. 
  • Ophthalmology issues in schizophrenia. 
  • Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. 
  • Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. 
  • Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects. 
  • Overconfidence in false autobiographical memories in patients with schizophrenia. 
  • PCM1 is necessary for focal ciliary integrity and is a candidate for severe schizophrenia. 
  • Partial REM sleep deprivation, schizophrenia and field articulation. 
  • Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia. 
  • Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. 
  • Patterns of justice involvement among adults with schizophrenia and bipolar disorder: key risk factors. 
  • Perceived burden and family functioning among informal caregivers of individuals living with schizophrenia in Tanzania: a cross-sectional study. 
  • Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. 
  • Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. 
  • Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. 
  • Persistent infection with neurotropic herpes viruses and cognitive impairment. 
  • Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. 
  • Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. 
  • Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. 
  • Pharmacotherapy of impaired affect in recovering schizophrenic patients. 
  • Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. 
  • Physiologic impairment of olfactory stimulus processing in schizophrenia. 
  • Placebo Response and Practice Effects in Schizophrenia Cognition Trials. 
  • Plasma dexamethasone concentrations and the dexamethasone suppression test. 
  • Platelet alpha 2-adrenergic receptors in schizophrenic patients before and after phenothiazine treatment. 
  • Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: a preliminary study. 
  • Platelet monoamine oxidase activity in schizophrenia. 
  • Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. 
  • Polydipsia screening tool 
  • Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. 
  • Polygenic risk score, genome-wide association, and gene set analyses of cognitive domain deficits in schizophrenia. 
  • Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. 
  • Polypharmacy in pregnant women with major psychiatric illness: a pilot study. 
  • Polysensoriality and Aesthetics: The Lived Sensory Experiences of Adults with Mental Illness. 
  • Positron emission tomography in neuropsychiatry. 
  • Predicting Schizophrenia. 
  • Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. 
  • Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. 
  • Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. 
  • Predictors of therapeutic response to haloperidol in acute schizophrenia. 
  • Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. 
  • Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. 
  • Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice. 
  • Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs. 
  • Premorbid sociosexual functioning and long-term outcome in schizophrenia. 
  • Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study. 
  • Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. 
  • Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. 
  • Principal components of heritability from neurocognitive domains differ between families with schizophrenia and control subjects. 
  • Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods. 
  • Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. 
  • Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. 
  • Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. 
  • Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. 
  • Psychiatric disorders. A rural/urban comparison. 
  • Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study. 
  • Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. 
  • Psychological morbidity of Thai families of a person with schizophrenia. 
  • Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. 
  • Psychoneuroendocrinology of schizophrenia. 
  • Psychopharmacology curriculum field test. 
  • Psychosocial factors in the neurobiology of schizophrenia: a selective review. 
  • Psychotic experiences and risk of death in the general population: 24-27 year follow-up of the Epidemiologic Catchment Area study. 
  • Racial Disparities in the Administration of ECT in Texas, 1998-2013. 
  • Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. 
  • Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. 
  • Reading problems, psychiatric disorders, and functional impairment from mid- to late adolescence. 
  • Readmission Patterns and Effectiveness of Transitional Care Among Medicaid Patients With Schizophrenia and Medical Comorbidity. 
  • Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. 
  • Reducing barriers to completing psychiatric advance directives. 
  • Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. 
  • Reduction of synapsin III in the prefrontal cortex of individuals with schizophrenia. 
  • Refining phenotype characterization in genetic linkage studies of schizophrenia. 
  • Refining the latent structure of neuropsychological performance in schizophrenia. 
  • Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study. 
  • Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia. 
  • Relationship of cognition and psychopathology to functional impairment in schizophrenia. 
  • Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. 
  • Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. 
  • Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia. 
  • Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. 
  • Religious coping and quality of life among individuals living with schizophrenia. 
  • Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. 
  • Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. 
  • Reproducibility probability in clinical trials. 
  • Response to Bora. 
  • Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives. 
  • Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms. 
  • Results of phase 3 of the CATIE schizophrenia trial. 
  • Revised PORT recommendations. 
  • Risks versus benefits of different types of long-acting injectable antipsychotics. 
  • Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. 
  • Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia. 
  • Schizophrenia is a cognitive illness: time for a change in focus. 
  • Schizophrenia is a disorder of higher order hierarchical processing. 
  • Schizophrenia polygenic risk score predicts mnemonic hippocampal activity. 
  • Schizophrenia, drug therapy, and monitoring. 
  • Schizophrenia, narrative, and neurocognition: The utility of life-stories in understanding social problem-solving skills. 
  • Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine. 
  • Science and recovery in schizophrenia. 
  • Scopolamine sleep treatment in private practise. 
  • Seizures terminable and interminable with ECT. 
  • Self-reported sleep disturbances associated with procedural learning impairment in adolescents at ultra-high risk for psychosis. 
  • Severe hyperglycemia associated with high doses of clozapine. 
  • Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. 
  • Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. 
  • Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. 
  • Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies. 
  • Single-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus. 
  • Slow-wave activity during non-REM sleep in men with schizophrenia and major depressive disorders. 
  • Smoking and therapeutic response to clozapine in patients with schizophrenia. 
  • Social functioning in urban, predominantly African American, socially disadvantaged patients with first-episode nonaffective psychosis. 
  • Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis. 
  • Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. 
  • Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. 
  • Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls. 
  • Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. 
  • Spectral and topographic analysis of EEG in schizophrenic patients. 
  • Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States. 
  • Stage-Specific Brain Aging in First-Episode Schizophrenia and Treatment-Resistant Schizophrenia. 
  • Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study. 
  • Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. 
  • Stigma and treatment delay in first-episode psychosis: a grounded theory study. 
  • Storm clouds over the public mental health safety net. 
  • Stratification-score matching improves correction for confounding by population stratification in case-control association studies. 
  • Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. 
  • Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. 
  • Substance use and mental diagnoses among adults with and without type 2 diabetes: Results from electronic health records data. 
  • Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. 
  • Substance use and schizophrenia: adverse correlates in the CATIE study sample. 
  • Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. 
  • Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. 
  • Supervised multimodal fusion and its application in searching joint neuromarkers of working memory deficits in schizophrenia. 
  • Sweet the sound. Music in medicine. 
  • Symptom profiles of psychiatric disorders based on graded disease classes: an illustration using data from the WHO International Pilot Study of Schizophrenia. 
  • Symptom-based patient stratification in mental illness using clinical notes. 
  • Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. 
  • Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls. 
  • Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. 
  • Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. 
  • The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. 
  • The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. 
  • The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. 
  • The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. 
  • The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. 
  • The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? 
  • The Function Biomedical Informatics Research Network Data Repository. 
  • The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. 
  • The History of Coordinated Specialty Care for Early Intervention in Psychosis in the United States: A Review of Effectiveness, Implementation, and Fidelity. 
  • The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. 
  • The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. 
  • The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. 
  • The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. 
  • The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. 
  • The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. 
  • The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. 
  • The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. 
  • The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. 
  • The Singapore flagship programme in translational and clinical research in psychosis. 
  • The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. 
  • The Texas Medication Algorithm Project Patient and Family Education Program: a consumer-guided initiative. 
  • The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. 
  • The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. 
  • The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm. 
  • The Texas medication algorithm project: clinical results for schizophrenia. 
  • The association between weight change and symptom reduction in the CATIE schizophrenia trial. 
  • The boundaries of schizophrenia. 
  • The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore. 
  • The costs of schizophrenia. 
  • The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. 
  • The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. 
  • The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. 
  • The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. 
  • The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. 
  • The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. 
  • The first clinical study of BW-234U in schizophrenia. 
  • The identification of psychiatric illness by primary care physicians: the effect of patient gender. 
  • The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. 
  • The impact of obesity on health care costs among persons with schizophrenia. 
  • The impact of posttraumatic stress disorder on quality of life and health service utilization among veterans who have schizophrenia. 
  • The importance of early treatment of schizophrenia. 
  • The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome. 
  • The influence of emotional distraction on verbal working memory: an fMRI investigation comparing individuals with schizophrenia and healthy adults. 
  • The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. 
  • The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. 
  • The intricate link between violence and mental disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. 
  • The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies. 
  • The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. 
  • The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. 
  • The period of untreated psychosis before treatment initiation: a qualitative study of family members' perspectives. 
  • The psychiatric use of electrically induced seizures. 
  • The relationship between negative symptom subdomains and cognition. 
  • The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. 
  • The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. 
  • The role of nuclear magnetic resonance imaging in psychiatric research. 
  • The severely mentally ill in general hospital psychiatric units. 
  • The targets of violence committed by young offenders with alcohol dependence, marijuana dependence and schizophrenia-spectrum disorders: findings from a birth cohort. 
  • The use of ECT within the Veterans Administration hospital system. 
  • Theta Burst for Cognitive Remediation in Schizophrenia: A Case Series and Feasibility Study. 
  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. 
  • Time-lapse mapping of cortical changes in schizophrenia with different treatments. 
  • Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. 
  • Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia. 
  • Transcriptome analysis of cortical tissue reveals shared sets of downregulated genes in autism and schizophrenia. 
  • Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. 
  • Treatment Outcomes of a Multi-Component Mobile Health Smoking Cessation Pilot Intervention for People with Schizophrenia. 
  • Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. 
  • Treatment participation and medication adherence: effects on criminal justice costs of persons with mental illness. 
  • Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. 
  • Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. 
  • Twin studies of psychopathology: why do the concordance rates vary? 
  • Understanding symbol coding in schizophrenia. 
  • Unirhinal olfactory function in schizophrenia patients and first-degree relatives. 
  • Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. 
  • Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. 
  • Unraveling the relationship between obesity, schizophrenia and cognition. 
  • Urinary excretion of biopterin and neopterin in psychiatric disorders. 
  • Use of ECT in the United States in 1975, 1980, and 1986. 
  • Use of Expert Consultation in a Complex Case of Neuroleptic Malignant Syndrome Requiring Electroconvulsive Therapy. 
  • Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. 
  • Using discriminant function analysis with clinical, demographic and historical variables to diagnose schizophrenia. 
  • Using the NIH Research, Condition and Disease Categorization Database for research advocacy: Schizophrenia research at NIMH as an example. 
  • Validation of a Computerized test of Functional Capacity. 
  • Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. 
  • Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results. 
  • Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. 
  • Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls. 
  • Validation of the tablet-administered Brief Assessment of Cognition (BAC App). 
  • Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia). 
  • Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. 
  • Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. 
  • Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. 
  • Ventricular enlargement in poor-outcome schizophrenia. 
  • Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. 
  • Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. 
  • Visual hallucinations are associated with hyperconnectivity between the amygdala and visual cortex in people with a diagnosis of schizophrenia. 
  • Voxel-based morphometric multisite collaborative study on schizophrenia. 
  • What CATIE found: results from the schizophrenia trial. 
  • What constitutes a psychiatric emergency: clinical and legal dimensions. 
  • Where do we cut the bell-shaped curve of CIAS? 
  • Whether ionizing radiation is a risk factor for schizophrenia spectrum disorders? 
  • White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study. 
  • Who are the new users of antipsychotic medications? 
  • Wisconsin Card Sorting Test performance in schizophrenia: the role of working memory. 
  • Working memory and schizophrenia: evidence for slowed encoding. 
  • Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment. 
  • [Problem of neuronal reception and the dopamine hypothesis of schizophrenia]. 
  • [Stimulating effect of schizophrenic patients' plasma on the cellular incorportation of tryptophan in vitro]. 
  • [The evaluation of cognitive dysfunctions in schizophrenia]. 
  • fMRI activity correlated with auditory hallucinations during performance of a working memory task: data from the FBIRN consortium study. 
  • rTMS strategies for the study and treatment of schizophrenia: a review. 
• 

  Keywords of People

  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Community Psychiatry
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology